Metagenomi, Inc. (Nasdaq:MGX)
Health Care/Life Sciences • Biotechnology
CIK 1785279
Company
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene editing toolbox, therapeutic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Address
5959 Horton Street
7th floor
Emeryville, California 94608
5959 Horton Street
7th floor
Emeryville, California 94608
Employees
236
236
Stock Info
Close
$1.9500
$1.9500
Day Range
1.8500 - 1.9600
1.8500 - 1.9600
52 Week Range
1.6100 - 12.3550
1.6100 - 12.3550
Average volume
2.29M
2.29M
Short Interest
2.57M (02/14/25)
2.57M (02/14/25)
% of Float Shorted
11.72%
11.72%
Market Cap
$72.98M
$72.98M
Revenue
$44.76M
$44.76M
Net Income
-$68.26M
-$68.26M
2020 Sales Growth
N/A
N/A
Key Executives
Board Of Directors
|
Chairman Jürgen Eckhardt |
|
Chief Executive Officer & Director Brian C. Thomas |
|
President, Chief Operating Officer & Director Jian Irish |
|
Director Sebastián Bernales |
|
Director Risa Stack |
|
Director Willard H. Dere |
|
Director Eric Hands Claude Bjerkholt |
SEC filings
| Date | Form | Event |
|---|---|---|
| 10 Dec, 2024 | 8-K | |
| 6 Dec, 2024 | 4 | |
| 13 Nov, 2024 | 10-Q | |
| 13 Nov, 2024 | 8-K | |
| 6 Nov, 2024 | SC 13G | |
| 6 Sep, 2024 | 4 | |
| 3 Sep, 2024 | 8-K | |
| 14 Aug, 2024 | 8-K | |
| 14 Aug, 2024 | 10-Q | |
| 14 May, 2024 | 8-K | |
| 14 May, 2024 | 10-Q | |
| 10 May, 2024 | SC 13G | |
| 1 May, 2024 | 8-K | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 3 Apr, 2024 | 4 | |
| 27 Mar, 2024 | 10-K | |
| 27 Mar, 2024 | 8-K | |
| 15 Feb, 2024 | 3 | |
| 15 Feb, 2024 | 4 | |
| 15 Feb, 2024 | 4 | |
| 14 Feb, 2024 | 4 | |
| 13 Feb, 2024 | 8-K | |
| 12 Feb, 2024 | 424B4 | IPO completed |
| 9 Feb, 2024 | S-8 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | CERT | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | 3 | |
| 8 Feb, 2024 | EFFECT | |
| 8 Feb, 2024 | SEC STAFF | |
| 7 Feb, 2024 | CORRESP | |
| 7 Feb, 2024 | S-1/A | |
| 6 Feb, 2024 | UPLOAD | |
| 6 Feb, 2024 | CORRESP | |
| 6 Feb, 2024 | CORRESP | |
| 5 Feb, 2024 | CORRESP | |
| 5 Feb, 2024 | S-1/A | |
| 5 Feb, 2024 | 8-A12B | |
| 18 Jan, 2024 | CORRESP | |
| 16 Jan, 2024 | CORRESP | |
| 8 Jan, 2024 | S-1/A | |
| 5 Jan, 2024 | CORRESP | |
| 5 Jan, 2024 | S-1 | |
| 20 Dec, 2023 | UPLOAD | |
| 11 Dec, 2023 | DRS/A | |
| 18 Sep, 2023 | SEC STAFF | |
| 7 Sep, 2023 | DRSLTR | |
| 7 Sep, 2023 | DRS/A | |
| 31 Aug, 2023 | UPLOAD | |
| 3 Aug, 2023 | DRS | |
| 11 Jan, 2023 | D | |
| 7 Feb, 2022 | D | |
| 29 Mar, 2021 | D |
Last update:2025-03-06 12:06:40.407087
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.